TLR7/8 agonists attached to BDC-1001 are phagocytosed into lysosomes on HER2-positive tumor cells, activating myeloid APCs and presenting tumor-associated antigens to T cells (Ackerman et al., 2019). Here, ERBB2 is linked to neoplasm.